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Letter to the EditorHemophagocytic lymphohistiocytosis in 2 pa-
tientswith underlying IFN-g receptor deficiency
To the Editor:
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyper-
inflammatory disorder, caused by mutations in genes required for
lymphocyte cytotoxicity or may be secondary to infections,
malignancy, and autoimmunity.1,2 Animal models have indicated
a central role for IFN-g produced by CD81 T cells in the patho-
physiology of HLH,3 and a possible clinical efficacy of anti–IFN-
g antibody therapy for the control of HLH.4
Here, we detail 2 unrelated cases of fatal IFN-g receptor (IFN-
gR) deficiency with mycobacterial infections who were initially
diagnosed with HLH. Patient A, a 2-month-old girl, and patient B,
a 4-year-old girl (see Case Reports and Fig E1, A and B, in this ar-
ticle’s Online Repository at www.jacionline.org), fulfilled, respec-
tively, 7 of 8 and 5 of 6 HLH diagnostic criteria1 (see Table E1 in
this article’s Online Repository at www.jacionline.org).
For information on methods, see this article’s Online Re-
pository at www.jacionline.org.FIG 1. Immunologic analyses. Both patients (A andB) di
in patient B were lower at initial diagnosis of HLH comp
analyses of patient A showed abnormal NK-cell degranu
(D), and normal granule content (E). Granule content (Fi
C) were normal in patient B. Ctrl, Control; R-MFI, relativIn patient A, cytotoxic lymphocyte function was evaluated
twice with the consistent finding of pathologically low natural
killer (NK)-cell cytotoxic function, even after IL-2 stimulation
(see Fig E2, A and B, in this article’s Online Repository at www.
jacionline.org). This reflected low NK cell numbers (Fig 1, A),
possibly caused by antithymocyte globulin treatment. NK-cell
cytotoxic activity was not evaluated in patient B because of the
very low frequency of peripheral blood NK cells, already present
at admission (Fig 1, B). In both patients, additional characteriza-
tion of NK-cell and T-cell function did not reveal defects consis-
tent with primary HLH caused by an impairment in lymphocyte
cytotoxicity (Fig 1, C-F; also see Fig E2, C and D). Accordingly,
no mutations were found in known HLH-associated genes.
After the diagnosis of HLH, the patients were found positive for
cytomegalovirus and Mycobacterium bovis infections, and for
EBV and Mycobacterium tuberculosis (MTB) infections, respec-
tively. Moreover, in patient B, plasma IFN-g levels were constitu-
tively elevated, without increasing further on stimulation with
mitogen or MTB antigen (see Fig E3, A and B in this article’s On-
line Repository at www.jacionline.org). In light of a disseminated
mycobacterial infection, a differential diagnosis of Mendeliansplayed a lownumber of NK cells. Neutrophil counts
ared with this later measurement. Flow-cytometric
lation toward K562 (C), normal T-cell degranulation
g 1, B) and NK-cell degranulation toward K562 (Fig 1,
e median fluorescence intensity; Trp, transport.
1
FIG 2. Coverage analysis in patient A suggests an exonic deletion of exon 2 of IFNGR2 (A), validated by RT-
PCR of IFNGR2 (B) and cDNA sequencing (C), which showed lack of exon 2. D, Sanger electropherograms of
G219R IFNGR1missense mutation in patient B. E, STAT1 phosphorylation on IFN-g stimulation is defective
in patient A, but not in the controls. Ctrl, Control; STAT1, signal transducer and activator of transcription 1;
Trp, transport.
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although fulminant HLH in the context of defective IFN-g
signaling was deemed unlikely.
In patient A, Sanger sequencing of IFNGR1 and IFNGR2 was
followed by whole exome sequencing. Variant calling did not
identify mutations able to explain the phenotype. Only a homo-
zygous missense variant in FANCA (p.H1417D), described in
patients with Fanconi anemia, was found. Instead, analysis of
copy number variation revealed a possible homozygous deletion
of exon 2 of IFNGR2 (Fig 2, A). Of note, exon 2 was not ampli-
fied by PCR. On evaluation of IFNGR2 transcripts, the patient
expressed only a truncated IFNGR2 transcript lacking exon 2
(c.74_216del, p.Asp25Alafs*38; Fig 2, B and C). In patient B,
sequencing of IFNGR1 and IFNGR2 revealed a homozygous
IFNGR1 c.655G>A (p.G219R) missense variant, affecting a
conserved residue in the second domain of the extracellular re-
gion of IFN-gR1. The parents and the healthy sister were het-
erozygous carriers (Fig 2, D). The G219R variant was
predicted damaging and was not found in the 1000 Genomes
database and in 150 healthy Chinese individuals. An in-frame
deletion affecting residue 218 of IFN-gR1 was described in a
patient with MSMD carrying compound heterozygous IFNGR1
mutations (the other mutation being p.V61Q), resulting in
normal IFN-gR1 surface expression but severely impaired
IFN-g binding.5 The G219R mutation may have a similar effect.
With mycobacterial infections and mutations in IFNGR1 orIFNGR2, the patients fulfilled a diagnosis of MSMD in addition
to HLH. A molecular defect in either chain of the IFN-gR het-
erodimer impairs signaling and causes increased susceptibility
to severe Mycobacterium species infections.6 After IFN-g stim-
ulation, no signal transducer and activator of transcription 1
phosphorylation was observed by flow cytometry in monocytes
from patient A (Fig 2, E), establishing a diagnosis of complete
IFN-gR deficiency. In patient B, it is not clear whether the IFN-
gR1 G219R mutation causes complete or partial IFN-gR1 defi-
ciency because such data were not available. Nonetheless, the
high levels of IFN-g found in patient B may suggest a complete
deficiency. Both the identified genetic aberrations were novel.
Importantly, this represents the first report of HLH in patients
with genetic aberrations impairing IFN-g signaling. Because
IFN-g is considered a cardinal cytokine in the development of
HLH, a link between HLH and defects in IFN-g signaling is
surprising.
Mouse models indicate a crucial role of IFN-g for the
development of primary HLH.3 Fatal HLH-like disease in Prf1
knockout mice infected with lymphocytic choriomeningitis virus
can be treated by antibody-mediated IFN-g neutralization.3
Intriguingly, antibody-mediated TNF neutralization ameliorated
organ damage in Prf1 knockout mice challenged with murine
cytomegalovirus.7 Moreover, in wild-type mice, high levels of
IL-4 or repeated Toll-like receptor 9 (TLR9) stimulation can
induce the development of an HLH-like or macrophage activation
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mice developed macrophage activation syndrome–like disease
with a severity comparable to that of wild-type mice, suggesting
that immune pathology may arise independent of IFN-g.9 This
model may provide an explanation for HLH in our patients.
DNA from M tuberculosis is a potent stimulus for TLR9-
dependent responses.10 We speculate that genetic susceptibility
to severe and sustained mycobacterial infection may predispose
to strong TLR stimulation, resulting in HLH. The low NK cell
numbers in our patient may have also enhanced the risk of devel-
oping HLH.
Interestingly, hemophagocytosis was not found in both cases.
Hemophagocytosis is often viewed as a late symptom and is not
required for a diagnosis of HLH.1 In mice, infusion of IFN-g can
induce hemophagocytosis by macrophages.11 Notably, such
macrophage-mediated macropinocytosis depends on IFN-gR
signaling in macrophages.11 Therefore, our patients may further
support a role for IFN-gR signaling in driving hemophagocytosis,
but not other pathologic features of the HLH syndrome.
Based on experiments in animal models, a clinical efficacy of
anti–IFN-g antibody treatment in patients with primary HLH has
been proposed.3,4 Clinical trials are ongoing, notably with active
infections, including mycobacterial, representing exclusion
criteria. Our findings suggest that other cytokines, for example,
TNF, may be important drivers of immune pathogenesis. In pa-
tients infected by multiple pathogens, blocking IFN-g may
accommodate other infections, leading to TLR stimulation and
HLH. Therefore, at least in settings of HLH associated with pri-
mary defects in immune function other than lymphocyte cytotox-
icity, immune suppression besides anti–IFN-g antibody should be
considered. It is noteworthy that antithymocyte globulin
controlled HLH in both patients.
In conclusion, we report 2 cases of HLH in children with novel
IFN-gR mutations. Importantly, our results highlight the signif-
icance of IFN-g–independent mechanisms in the immune pathol-
ogy of HLH, provide new views on pathogenic mechanisms of
human hyperinflammatory syndromes, and expand the spectrum
of genetic conditions conferring susceptibility to HLH. Clinically,
because different mechanisms seem to be involved in HLH
pathogenesis, novel therapies, beside anti–IFN-g therapy, should
be investigated.
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CASE REPORTS
Patient A, a 2-month-old girl, born to consanguineous Portu-
guese parents (Fig E1, A), was initially admitted for impetigi-
nized atopic eczema treated with flucloxacilin, which
triggered an episode resembling a drug reaction with eosino-
philia and systemic symptoms syndrome. Subsequently, she
developed worsening fever, hepatosplenomegaly with chole-
static hepatitis, hyperferritinemia, hypofibrinogenemia, as well
as thrombocytopenia, anemia, and elevated sCD25 level
(Table E1). Hemophagocytosis was not evident in bone marrow,
liver, or skin. The patient fulfilled 7 of 8 HLH diagnostic criter-
ia,E1 establishing a diagnosis of HLH (Table E1). HLH treatment
was initiated with dexamethasone, antithymocyte globulin, and
cyclosporine, resulting in partial control of disease. Subse-
quently, the patient was found positive for cytomegalovirus
(>10,000,000 viral copies/mL) and for Mycobacterium bovis
in bone marrow and hepatic culture. Despite treatment for the in-
fections, the clinical conditions worsened and the patient devel-
oped acute respiratory distress syndrome with fatal outcome at
the age of 4.5 months.
Patient B, a 4-year-old girl, was born in Italy to apparently
nonconsanguineous Chinese parents (Fig E1, B). The patient
was admitted for persistent fever, leucocytosis, and a medias-
tinal mass. She subsequently developed hepatosplenomegaly,
anemia, neutropenia, thrombocytopenia, hypertriglyceride-
mia, and hyperferritinemia. Bone marrow aspirate, performed
twice, did not show hemophagocytosis. However, the patient
fulfilled 5 of 6 HLH diagnostic criteria examined (Table
E1). The patient was positive for EBV infection (180,000 viral
copies/mL), while tuberculin skin and Quantiferon-TB test re-
sults were, respectively, negative and indeterminate. Interest-
ingly, plasma IFN-g levels were constitutively high, without
further increase in response to mitogen or TB-antigen stimu-
lation (Fig E3, A and B). Dexamethasone, anti-CD20, and
cyclophosphamide and gancyclovir were administrated, lead-
ing to partial remission of HLH and infection control. Two
weeks later, the patient reactivated (with ferritin up to
395,644 ng/mL) and developed life-threatening conditions.
Rabbit antithymocyte globulin was administered with sudden
improvement, albeit persistent fever and the onset of ocular
and neurologic symptoms. At this point, disseminated infec-
tion by M tuberculosis was diagnosed by PCR and cultures
of blood, cerebral spinal fluid, and eye swab. A 5-drug antitu-
bercular therapy was started with transient control followed
by death from multiorgan failure.
METHODS
The studies were approved by the Regional Ethical Review Board in
Stockholm, Sweden, and by the Regional Committee in Florence, Italy.
Genetic analyses
Genomic DNAwas isolated from peripheral blood according to a standard
procedure. Informed consent was obtained from the patients and their
relatives. Genes responsible for familial HLH, IFNGR1, and IFNGR2 were
analyzed by direct sequencing. For patient A, whole exome sequencing was
performed on a HiSeq2000 Illumina machine. Agilent SureSelect v51UTRs
kit was used for target enrichment. The sequencing reads were aligned to the
human genome build37 (hg19) using BWA/0.7.4.E2 Unified Genotyper GATK
(v.2.5)E3 and Annovar software (version 2013Jun21)E4 were used for variant
calling and annotation, respectively. Copy number variations were analyzed
with the R package ExomeDepth.E5 RNA was isolated from blood or fibro-
blasts of patient A and her family members and used for cDNA synthesis
and evaluation of IFNGR2 transcripts according to standard procedures.
Primers are available on request. One hundred and fifty healthy controls of
Chinese ethnicity were analyzed for themissense variant in IFNGR1 identified
in patient B. Primers are available on request.
Immunologic analyses
Absolute lymphocyte counts were performed according to standard pro-
cedures (Trucount, BD Biosciences, San Jose, Calif). PBMCs were isolated by
density gradient centrifugation (Lymphoprep, Axis-Shield, Dundee, United
Kingdom)andmaintained in completemedium (RPMI-1640 supplementedwith
2mML-glutamine and 10%FBS; all Hyclone, SouthLogan,Utah). Intracellular
expression of perforin was evaluated by using flow cytometry in both patients as
previously described.E6NK-cell and cytotoxicT lymphocytes degranulationwas
assessed by using flow cytometry as previously described.E7 NK-cell cytotox-
icity against K562 target cells was evaluated in patient A with a standard 4-
hour 51Cr-release assay using PBMCs, as previously described.E8 To evaluate
signal transducer and activator of transcription 1 signaling, PBMCs from patient
A were thawed and stained, after overnight incubation, with fixable dead cell
stain (Invitrogen, Carlsbad, Calif). PBMCs (1 3 106) were resuspended and
either left untreatedor stimulatedwith 500U/mL IFN-a (PBLInterferonSource,
Logan, Utah) or 100 ng/mL IFN-g (Peprotech, Rocky Hill, NJ) for 30 minutes.
The cellswere fixed,washed inPBS, and permeabilized for 30minutes at2208C
(Perm Buffer III, BD Biosciences). The cells were thereafter stained with anti-
CD14 and anti–signal transducer and activator of transcription 1 pY701 anti-
bodies (both BD Biosciences). The cells were washed and analyzed by using
flow cytometry (LSR Fortessa, BD Biosciences). Dead cells were excluded
and monocytes identified by forward scatter and side scatter characteristics
and CD14 staining. All analyses were performed using FlowJo software
(v9.7.5; Tree Star, Ashland, Ore). IFN-g release assay was performed using
the Quantiferon-TB Gold test (Qiagen, Hilden, Germany) following the manu-
facturer’s instructions. Briefly, whole blood was incubated for 16 hours at
378Cwith mitogen (positive control), TB antigen, or nothing (negative control),
respectively. Plasma IFN-g levels were then quantified using an ELISA plate.
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FIG E1. Family pedigree of patient A (II-3) (A) and patient B (II-1) (B).
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FIG E2. NK-cell cytotoxic activity measured in patient A in resting NK cells (A) and after stimulation with IL-2
(B). Flow-cytometry analyses of NK-cell (Fig E2, A) and T-cell (Fig E2, B) degranulation after stimulation with
IL-2 in PBMCs from patient A. Ctrl, Control; Trp, transport.
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FIG E3. IFN-g release by patient B and control PBMCs. IFN-g release was
evaluated with 2 different assays that quantified IFN-g by active units (A) or
concentration (B). Ctrl, Control.
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TABLE E1. Clinical and laboratory findings of the patients at
disease onset
Finding A B
Ethnical origin Portuguese Chinese
Familial disease No No
Parental consanguinity Yes No
Sex Female Female
Age at diagnosis of HLH 2 mo 4 y
Fever Yes Yes
Splenomegaly Yes Yes
Hepatomegaly Yes Yes
Hb (g/L) 67 77
Neutrophils (109/L) 2.5 6.7
Platelets (109/L) 10 21
Triglycerides (mmol/L) 15.2 7.4
Fibrinogen (g/L) 0.9 2.7
Hemophagocytosis No No
Ferritin (ng/mL) 5,434 36,292
sCD25 (U/mL) >200,000 nd
NK-cell activity* Defective nd
NK-cell degranulation Normal Normal
Neurologic manifestations None None
Pathologic CSF nd nd
Treatment of active disease Dexa, CsA, ATG Dexa, VP16, ATG
Remission at 2 mo Yes No
Age at HSCT Not done Not done
Outcome Deceased Deceased
ATG, Antithymocyte globulin; CsA, cyclosporine A; Dexa, dexamethasone; HSCT,
hematopoietic stem cell transplantation; nd, no data; VP16, ethoposide.
*Defective: 10 lytic units or less.
Reported at some point during the course of the disease.
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